Singapore markets closed
AIRLINES

Omicron’s rapid spread shreds budding recovery in air travel

Prothena Corporation plc (PRTA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
44.06-2.53 (-5.43%)
At close: 04:00PM EST
44.06 0.00 (0.00%)
After hours: 05:29PM EST

Prothena Corporation plc

77 Sir John Rogerson’s Quay
Block C Grand Canal Docklands
Dublin 2
Ireland
353 1 236 2500
https://www.prothena.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees66

Key executives

NameTitlePayExercisedYear born
Dr. Gene G. Kinney Ph.D.Pres, CEO & Director901.12kN/A1969
Mr. Tran B. Nguyen M.B.A.CFO & Chief Strategy Officer679.37kN/A1974
Mr. Brandon S. SmithChief Operating Officer580.92kN/A1975
Mr. Michael J. MalecekChief Legal Officer & Company Sec.588.25kN/A1966
Ms. Carol D. KarpChief Regulatory Officer624.39kN/A1953
Ms. Karin L. Walker CPAChief Accounting Officer & ControllerN/AN/A1963
Dr. Wagner M. ZagoChief Scientific OfficerN/AN/A1973
Ms. Jennifer ZibudaDirector of Investor Relations & CommunicationN/AN/AN/A
Dr. Radhika Tripuraneni M.P.H., M.D.Chief Devel. OfficerN/AN/A1980
Dr. Hideki GarrenChief Medical OfficerN/AN/A1965
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.

Corporate governance

Prothena Corporation plc’s ISS governance QualityScore as of 26 September 2021 is 5. The pillar scores are Audit: 8; Board: 4; Shareholder rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.